ArticleCureus2025
Identifying Leukopenia, Renal Dysfunction and Other Factors Limiting Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer: A Way to Focus on the Importance of Supportive Care and Potentially Improve Treatment Results?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConcomitant chemoradiotherapy (CHRT) with weekly cisplatin and image-guided adaptive brachytherapy (IGABT) is the standard treatment for unresectable locally advanced cervical cancer. It has been shown that receiving five or more cycles of concomitant chemotherapy (CHT) significantly improves recurrence-free and overall survival. In this study, we analysed the factors contributing to the omission of concomitant chemotherapy within a patient cohort.
methodsIn this single-centre retrospective study, we analysed medical records of 191 patients treated at our facility (Department of Oncology and Radiotherapeutics, University Hospital Pilsen, Czech Republic) from 2012 to 2024 to identify factors preventing optimal CHT administration. Included patients were those with newly diagnosed locally advanced, unresectable cervical cancer, where concomitant platinum-based CHRT with IGABT was indicated.
resultsOf the patients, 15% (29/191) received no concomitant CHT, primarily due to concerns about toxicity, patient frailty/comorbidities, and renal insufficiency, with a statistically significant age difference in those who received CHT versus those who did not: mean 55.03 (±SD11.89) vs. 63.52 (±SD12.14) years (95% CI 3.74-13.23, p=0.0005). Among patients who initiated concomitant CHT but received four or fewer cycles (92/162, 57%), leukopenia was the most common independent limiting factor, followed by decreased renal function. Other factors included nausea, diarrhea, and administrative reasons.
conclusionLeukopenia and renal dysfunction were primary barriers to completing optimal concomitant CHT in a significant number of patients. We advocate for increased emphasis on supportive care, including granulocyte colony-stimulating factor (G-CSF) use in leukopenia/neutropenia prevention or treatment, and meticulous management of renal functions. Individualized renal assessment, not just 'cisplatin-unfit' criteria, is crucial. Further research on G-CSFs in CHRT is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.